ObsEva SA (OBSV)
(Delayed Data from NSDQ)
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[OBSV]
Reports for Purchase
Showing records 61 - 80 ( 170 total )
Industry: Medical - Biomedical and Genetics
Nolasiban China Deal Inked; PRIMROSE 1 Data Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Nolasiban/IVF: Exclusive License Agreement with Yuyuan in China
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Show Some Appreciation; PRIMROSE 2 Data Puts Bloom on Linzagolix; Reiterate Buy; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix without ABT is Likely to Achieve Front Line for UF
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Nolasiban Nullified; Linzagolix Data Imminent; Reiterate Buy and Lowering Target to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Q3 Financials: Nolasiban Discontinued; Key Catalysts Anticipated in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
We reiterate our OUTPERFORM rating and our twelve-month PT of $38
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
IMPLANT 3 Protocol Authorized; Multiple Recent Data Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Potential Buying Opportunity Ahead of Near-Term Material Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Linzagolix Presentations at Upcoming Medical Conferences
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
ASRM Preview: Clinical Data on Nolasiban and Linzagolix
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Mechanism of Action Study Bolsters Nolasiban Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Nolasiban/IVF: New Data Reinforces Our Bullish View; Ph3 IMPLANT4 Results in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Higher R-D Spending; Credit Facility Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R